ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Microscopic Polyangiitis"

  • Abstract Number: 0698 • ACR Convergence 2024

    Association of Systemic Sclerosis with ANCA-Associated Vasculitis and Large Vessel Vasculitis: Impact of Pulmonary Arterial Hypertension

    Brett Dinner1, Ahmed Abdelmaksoud2, Ann Igoe3, Taylor Viggiano4 and Vivek Nagaraja5, 1Creighton University, Paradise Valley, AZ, 2University of California, Riverside, Riverside, CA, 3Flow, Tempe, AZ, 4Mayo Clinic, Phoenix, 5Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disorder with excessive fibrosis and vasculopathy. While typically non-inflammatory, frank vasculitis can complicate SSc. Concomitant SSc with ANCA-associated…
  • Abstract Number: 1608 • ACR Convergence 2024

    Interstitial Lung Disease in ANCA-associated Vasculitis: A Retrospective Study of Clinical Characteristics, Radiographic Features, and Outcomes

    Janelle Castellino1, Matas Orentas2, Joshua Moran3, Joshlean Fair1, Yanyu Zhang4 and Aleksandra Bukiej5, 1Rush University Medical Center, Chicago, IL, 2RUMC, Chicago, IL, 3Rush University Medical Center - IM Residency, Chicago, IL, 4Rush University Medical Center, Chicago, 5Rush University Medical Center, River Forest, IL

    Background/Purpose: Interstitial lung disease (ILD) is a significant manifestation of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and…
  • Abstract Number: 2181 • ACR Convergence 2024

    Large Pediatric Cohort with ANCA-associated Vasculitis at a Single Institution: Patient Characteristics, Clinical Course, and Outcomes

    Jessica Bloom1, Anna Monley2, Sarah Reingold3, Robert Fuhlbrigge1 and Peter Merkel4, 1University of Colorado, Denver, CO, 2University of Colorado, Aurora, CO, 3Denver Health, Denver, CO, 4University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is an understudied, chronic inflammatory disease in children with significant morbidity and mortality. There are few large pediatric cohorts…
  • Abstract Number: 2478 • ACR Convergence 2024

    Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial

    Christian Pagnoux1, Antoine Neel2, Sarah Bray3, Rachel E. Gurlin4, Darcy Trimpe5, David Jayne6 and Peter Merkel7, and ADVOCATE Study Group, 1Mount Sinai Hospital, Toronto, ON, Canada, 2Department of Internal Medicine, CHU Nantes, Nantes, France, 3Amgen Ltd, Cambridge, United Kingdom, 4Amgen Inc., Mountain View, CA, 5Amgen Inc., Thousand Oaks, CA, 6University of Cambridge, Cambridge, United Kingdom, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are subtypes of ANCA-associated vasculitis that frequently involve the kidneys. However, a subset of patients with…
  • Abstract Number: 2480 • ACR Convergence 2024

    Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial

    Robert Spiera1, Robert Lebovics2, Sarah Bray3, Rachel E. Gurlin4, David Jayne5 and Peter Merkel6, and ADVOCATE Study Group, 1Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 2Hackensack Meridian University Health System, Hackensack, NJ, 3Amgen Ltd, Cambridge, United Kingdom, 4Amgen Inc., Mountain View, CA, 5University of Cambridge, Cambridge, United Kingdom, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: In the phase 3 ADVOCATE trial, 45.2% and 42.1% of patients in the avacopan and prednisone taper groups, respectively, had active ear, nose, or…
  • Abstract Number: 2486 • ACR Convergence 2024

    Glucocorticoids May Mitigate the Risk of Avacopan-Induced Liver Dysfunction in ANCA-Associated Vasculitis: Data from a Multicenter Observational Study in Japan

    Tomohisa Uchida1, Shoichi Fukui1, Naoki Iwamoto1, Ayaka Umetsu2, Momoko Okamoto2, Keita Fujikawa2, Akinari Mizokami2, Takuya Tomokawa3, Kazusato Hara3, Yoshiro Horai3 and Atsushi Kawakami4, 1Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Rheumatology, Japan Community Healthcare Organization (JCHO) Isahaya General Hospital, Isahaya, Japan, 3Department of Rheumatology, Sasebo City General Hospital, Sasebo, Japan, 4Nagasaki University, Nagasaki, Japan

    Background/Purpose: Avacopan, a C5a receptor inhibitor, has emerged as a novel treatment for ANCA-associated vasculitis (AAV), providing an alternative to glucocorticoids1. Despite its promising potential,…
  • Abstract Number: 2488 • ACR Convergence 2024

    Patient Characteristics and Treatment Patterns Before and After Initiation of Avacopan in the United States: An Early View Based on a Claims Database Analysis

    Sushmitha Inguva1, Pallavi Rane1, Darcy Trimpe1, Sam Oh1, Jasjit Multani2, Hsiu-Ching Chang2, Marie Yasuda2, Chi-Chang Chen2, Duvuru Geetha3, Peter Merkel4 and Zachary Wallace5, 1Amgen Inc., Thousand Oaks, CA, 2IQVIA, Wayne, PA, 3Johns Hopkins University, Baltimore, MD, 4University of Pennsylvania, Philadelphia, PA, 5Massachusetts General Hospital, Newton, MA

    Background/Purpose: The United States (US) Food and Drug Administration approved avacopan to treat adults with severe active granulomatosis with polyangiitis or microscopic polyangiitis in October…
  • Abstract Number: 2689 • ACR Convergence 2024

    Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis

    Lynn Fussner1, Ivan Bilic2, Carol McAlear3, David Cuthbertson4, Jie Cheng5, Elise Chen5, Markus Weiller2, Ulrich Specks6 and Peter Merkel3, and for the Vasculitis Clinical Research Consortium, 1The Ohio State University, Columbus, OH, 2Takeda Pharmaceuticals, Vienna, Austria, 3University of Pennsylvania, Philadelphia, PA, 4University of South Florida, Tampa, FL, 5Takeda Pharmaceuticals, Cambridge, MA, 6Mayo Clinic, Rochester, MN

    Background/Purpose: Two separate genome-wide association studies demonstrated that polymorphisms in SERPINA1, encoding serine protease inhibitor alpha-1 antitrypsin (A1AT), are associated with increased risk of developing…
  • Abstract Number: 0697 • ACR Convergence 2024

    Association of ANCA-Associated Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension

    Brett Dinner1, Ahmed Abdelmaksoud2, Ann Igoe3, Taylor Viggiano4 and Vivek Nagaraja5, 1Creighton University, Paradise Valley, AZ, 2University of California, Riverside, Riverside, CA, 3Flow, Tempe, AZ, 4Mayo Clinic, Phoenix, 5Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a spectrum of autoimmune disorders characterized by necrotizing small-to-medium vessel inflammation and circulating ANCAs. Represented by granulomatosis…
  • Abstract Number: 0681 • ACR Convergence 2023

    Real-World Outcomes for Remission Induction in Working-Age Adults with Severe Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis

    Itay Marmor1, Katelin Nickel2, Matthew Keller2, Guy Hazan3, Kevin Baszis4, Anthony French5 and Mary Hartman2, 1Dana-Dwek Children's Hospital, Hod Hasharon, Israel, 2Washington University in St. Louis, St. Louis, MO, 3Soroka University Medical Center, Beer Sheva, Israel, 4Washington Univ in St. Louis School of Medicine, St. Louis, MO, 5Washington University School of Medicine, St. Louis, MO

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), often manifests with life-threatening complications. Cyclophosphamide (CYC) and rituximab…
  • Abstract Number: 0684 • ACR Convergence 2023

    Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

    Ulrich Specks1, David Jayne2 and Peter Merkel3, 1Mayo Clinic, Rochester, MN, 2University of Cambridge, Cambridge, United Kingdom, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Although respiratory tract involvement in ANCA-associated vasculitis (AAV) is frequent and associated with increased mortality, studies focusing on diffuse alveolar hemorrhage (DAH) in AAV…
  • Abstract Number: 0685 • ACR Convergence 2023

    Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial

    Duvuru Geetha1, Anisha Dua2, Huibin Yue3, Carlo Salvarani4, David Jayne5 and Peter Merkel6, 1Johns Hopkins University, Baltimore, MD, 2Northwestern University, Chicago, IL, 3Amgen, Inc., Thousand Oaks, CA, 4Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 5University of Cambridge, Cambridge, United Kingdom, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The randomized, double-blind, double-dummy, controlled Phase 3 ADVOCATE trial tested whether avacopan, an oral selective C5a receptor inhibitor approved for the treatment of ANCA-associated…
  • Abstract Number: 0686 • ACR Convergence 2023

    Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis

    David Jayne1, Duvuru Geetha2, Christian Pagnoux3, Sebastian Sattui4 and Peter Merkel5, 1University of Cambridge, Cambridge, United Kingdom, 2Johns Hopkins University, Baltimore, MD, 3Mount Sinai Hospital, Toronto, ON, Canada, 4University of Pittsburgh, Pittsburgh, PA, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Older adults are at increased risk of glucocorticoid (GC)-related toxicity; minimization of GCs is a major focus for treatment of patients with ANCA-associated vasculitis…
  • Abstract Number: 0689 • ACR Convergence 2023

    Use of Avacopan in Patients with ANCA-associated Vasculitis and Estimated Glomerular Filtration Rate < 15 mL/min/1.73m2

    Bryce Barr, Kim Cheema, Aurore Fifi-Mah, Stephanie Garner, Louis Girard and Jeffrey Ma, University of Calgary, Calgary, AB, Canada

    Background/Purpose: Glomerulonephritis represents a severe manifestation of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) and is associated with substantial morbidity and mortality. Therefore, maximal recovery…
  • Abstract Number: 0725 • ACR Convergence 2023

    Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

    Sophie Nagle1, Yann Nguyen2, Xavier Puéchal3, Dimitri Titeca-Beauport4, Thomas Crépin5, Rafik Mesbah6, Idris Boudhabhay7, Gregory Pugnet8, Juliette Woessner9, Roderau Outh10, Céline Lebas11, Antoine Néel12, alexandre Karras13, Eric Hachulla11, Benjamin Subran14, Philippe Kerschen15, Mathieu Gerfaud-Valentin16, Stéphane Vinzio17, Tiphaine Goulenok18, Raphael Borie19, Sébastien Humbert20, Yurdagul Uzunhan21, Sarah Melboucy-Belkhir22, Jean-Baptiste Gouin23, Mary-Jane Guerry24 and Benjamin Terrier25, 1AP-HP Cochin Hospital, Paris, France, 2Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 4CHU Amiens, Amiens, France, 5Amiens University Hospital, Amiens, France, 6Boulogne Hospital (CH), Boulogne, France, 7Necker University Hospital, Paris, France, 8CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, 9Avignon Hospital (CH), Avignon, France, 10Perpignan Hospital (CH), Perpignan, France, 11Lille University Hospital, Lille, France, 12CHU Nantes, Nantes, France, 13HEGP - APHP, Paris, France, 14Croix Saint Simon Hospital, Paris, France, 15Department of Neurology, Luxembourg Hospital Center, Luxembourg City, Luxembourg, 16Lyon University Hospital, Lyon, France, 17Grenoble Hospital (CH), Grenoble, France, 18Assistance Publique Hopitaux de Paris, Paris, France, 19Bichat-Claude Bernard, Universite de Paris, Paris, France, 20Besançon University Hospital, Besançon, France, 21AP-HP, Bobigny, France, 22Saint Quentin Hospital, Saint-Quentin, France, 23Vannes Hospital (CH Bretagne Atlantique), Vannes, France, 24Valenciennes Hospital (CH), Valenciennes, France, 25Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Glucocorticoids (GCs) in combination with rituximab (RTX) or cyclophosphamide are the cornerstone of treatment for patients with severe granulomatosis with polyangiitis (GPA) and microscopic…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology